Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Rhea-AI Summary

DBV Technologies has published its Half-Year Report on the liquidity contract with ODDO BHF as of December 31, 2021.

The liquidity account contained 153,631 shares worth €175,542.33, compared to 24,313 shares and €682,454.94 at the contract's inception in July 2018. In 2021's second half, 1,206 shares were purchased and 1,065 sold, totaling 455,657 shares bought for €3,256,011.54 and 379,901 sold for €2,951,075.39. DBV is advancing Viaskin™, a non-invasive immunotherapy platform targeting food allergies.

Positive

• DBV Technologies has a robust liquidity position with €175,542.33 as of December 31, 2021.
• The increase in shares held in the liquidity contract from 24,313 to 153,631 reflects improved market confidence.

Negative

• The liquidity account's cash has significantly decreased from €682,454.94 at the inception of the contract to €175,542.33.
• The total value of shares traded indicates a potential decline in investor interest, with higher purchases (€3,256,011.54) versus sales (€2,951,075.39).

AMF REGULATED INFORMATION
Montrouge, France, January 21, 2022

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.

As of December 31, 2021, the following assets appeared on the liquidity account:

• 153,631 DBV Technologies shares;
• € 175,542.33.

Upon signing the liquidity contract in July 2018, the following resources appeared on the liquidity account:

• 24,313 DBV Technologies ordinary shares;
• € 682,454.94.

Number of transactions executed during the second half-year of 2021:

• Purchase: 1,206
• Sale: 1,065

Over the same period, the volumes traded represented:

• 455,657 DBV Technologies ordinary shares purchased for €3,256,011.54
• 379,901 DBV Technologies ordinary shares sold for €2,951,075.39

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com 

Attachment

• PDF Version

FAQ

What is the latest liquidity report for DBVT?

DBVT's latest liquidity report as of December 31, 2021, shows 153,631 shares valued at €175,542.33.

How many transactions did DBVT execute in the second half of 2021?

DBVT executed 1,206 purchases and 1,065 sales during the second half of 2021.

What is the trend in DBVT's liquidity contract since its inception?

Since its inception in July 2018, DBVT's liquidity contract has seen a decrease in cash and a significant increase in shares held.

What is Viaskin™ by DBV Technologies?

Viaskin™ is an investigational immunotherapy platform aimed at safely transforming the care of food allergic patients.